Longeveron (LGVN) Retained Earnings (2021 - 2026)
Longeveron's (LGVN) quarterly Retained Earnings came in at $153.0 million in Q1 2026, up 233.55% year-on-year from $45.9 million in Q1 2025, and up 10.93% quarter-over-quarter from $138.0 million in Q4 2025.
Longeveron (LGVN) Retained Earnings (2021 - 2026) Analysis & Trends
Longeveron's Retained Earnings history runs 6 years deep, the most recent figure standing at $153.0 million for Q1 2026.
- On a quarterly basis, Retained Earnings rose 233.55% year-over-year to $153.0 million in Q1 2026; TTM through Mar 2026 was $153.0 million, a 233.55% increase from a year earlier, with the FY2025 full-year figure at $138.0 million, up 4.93% from the prior year.
- Retained Earnings advanced to $153.0 million in Q1 2026 per LGVN's latest filing, from $138.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $153.0 million in Q1 2026 and bottomed at -$126.9 million in Q3 2025.
- The 5-year median for Retained Earnings is -$39.7 million (2022), against an average of -$9.6 million.
- Across the five-year window, Retained Earnings slumped 23705.04% in 2023 and soared 13228900.0% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$357000.0 in 2022, then slumped by 23705.04% to -$85.0 million in 2023, then soared by 254.71% to $131.5 million in 2024, then rose by 4.93% to $138.0 million in 2025, then increased by 10.93% to $153.0 million in 2026.
- Per Business Quant, the three latest LGVN Retained Earnings figures stand at $153.0 million (Q1 2026), $138.0 million (Q4 2025), and -$126.9 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 153.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.04 Mn |
| Dec 31, 2025 | 137.96 Mn |
| Sep 30, 2025 | -126.87 Mn |
| Jun 30, 2025 | 132.29 Mn |
| Mar 31, 2025 | -114.60 Mn |
| Dec 31, 2024 | 131.48 Mn |
| Sep 30, 2024 | -105.53 Mn |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -89.04 Mn |
| Dec 31, 2023 | -84.98 Mn |
| Sep 30, 2023 | -78.96 Mn |
| Jun 30, 2023 | -335,000.00 |
| Mar 31, 2023 | -89.00 Mn |
| Dec 31, 2022 | -357,000.00 |
| Dec 31, 2021 | 81.47 Mn |